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ABSTRACT
Objective: We analyzed the effect of neoadjuvant chemo-
radiation on feasibility and outcomes in rectal cancer pa-
tients undergoing laparoscopic resection of the rectum.
Methods: This was a retrospective analysis of a consec-
utive series of laparoscopic resections for rectal cancer
from 1998 to 2004 (N60).
Results: Eight patients received preoperative chemora-
diation therapy (neoadjuvant group) for rectal cancer and
52 patients did not (primary surgical group). The conver-
sion rate was higher in the neoadjuvant group, but this did
not reach statistical significance (3/8, 37% in the neoadju-
vant group vs. 7/52, 13% in the primary surgical group,
P0.12). Operative time was longer in the neoadjuvant
group (17060 vs 22870 min, P0.03). Complication
rates (3/52, 5.7% in the primary surgical vs. 0% in the
neoadjuvant group, P1.0), and a median number of
resected lymph nodes (14.5 in the primary surgical vs.
16.0 in the neoadjuvant group, P0.81) were similar be-
tween groups.
Conclusion: Laparoscopic resection of rectal cancer in
patients after preoperative chemoradiation treatment
seems to be associated with a higher conversion rate and
a longer duration of surgery. No change in mortality and
morbidity was detected. We encourage further investiga-
tion of laparoscopic rectal surgery for treatment of rectal
cancer.
Key Words: Rectal cancer, Laparoscopic resection, Neo-
adjuvant chemoradiation.
INTRODUCTION
Laparoscopic resection of the colon is an accepted option
for surgical treatment of colon cancer. Oncologic ade-
quacy is supported by both prospective randomized da-
ta1,2 and multiple retrospective analyses.3–5
However, no comparable evidence is available to support
laparoscopic resection of rectal cancer at this time. Retro-
spective studies cautiously report both oncological com-
petence and the technical challenge associated with lapa-
roscopic rectal resections.6,7 Initial data from the rectal
cancer data set in the CLASSIC trial8 also support clinical
and oncologic noninferiority. Although laparoscopic rec-
tal resection appears safe, certain concerns remain regard-
ing increased conversion rates and associated complica-
tions.8
Additionally, the benefits of preoperative radiotherapy in
improving local control9,10 and overall survival10 were
recognized in the past decade. On the other hand, the
addition of preoperative radiation therapy has led to in-
creased perioperative mortality in some patients.10,11
Therefore, we analyzed the effects of neoadjuvant therapy
on feasibility and outcomes in patients undergoing lapa-
roscopic rectal resection for rectal cancer.
METHODS
We retrospectively analyzed consecutive patients diag-
nosed with rectal carcinoma from December 1998 to No-
vember 2004 who underwent laparoscopic rectal resec-
tion. All patients of the 2 laparoscopic surgeons were
offered a laparoscopic approach, and most accepted this
option. Patients with tumors of the middle or lower third
of the rectum (such as within 8cm of the anal verge) and
bulky tumors were offered open resection only during the
initial years of this study. All patients had total mesorectal
resection. Patients with frank perforation and acute ob-
struction are not included in this study. Patients with a
history of prior abdominal operations and metastasis are
included. All patients received a bowel preparation, pre-
operative antibiotics, subcutaneous heparin, and -block-
ers as indicated.
The choice of adjuvant versus neoadjuvant therapy was
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SCIENTIFIC PAPERguided by a clinical consensus of the surgeon and medical
and radiation oncologists and was not randomized. In
cases of neoadjuvant radiation therapy, a dose of 50 Gy
radiation was delivered in 2.0 Gy per fraction. All patients
receiving neoadjuvant radiation were given concurrent
chemotherapy. The medical oncologist determined the
choice of chemotherapy. Demographic parameters of
both groups are similar.
Categorical data were cross-tabulated and analyzed by the
chi-square test or Fischer exact test where appropriate.
Continuous data were evaluated by the Mann-Whitney
test, and survival was examined by the Kaplan-Meier
method. Statistical significance was set at P0.05.
RESULTS
The study included 60 consecutive patients with a mean
age of 70.4 years. Fifty-two patients (86.7%) did not re-
ceive neoadjuvant therapy and went directly to surgery
(primary surgical group). Eight patients (13.3%) received
neoadjuvant therapy in their preoperative course (neoad-
juvant group).
During the study period, approximately 250 laparoscopic
colorectal cases were completed annually. Patients with
rectal cancer were determined to have procedures either
attempted laparoscopically or in an open fashion.
Fifty patients (83.3%) had successfully completed laparo-
scopic procedures. Ten patients (10/60, 16.7%) were con-
verted to open procedures, of which 7 patients were from
the primary surgical group (7/52, 13.4%) and 3 were from
the neoadjuvant group (3/8, 37.5%; odds ratio 3.8,
P0.120).
Fourteen patients (14/60, 23.3%) underwent abdomino-
perineal resection (APR), and 46 patients (46/60, 76.6%)
had low anterior resection (LAR). Neoadjuvant therapy
was more common in those patients who eventually un-
derwent APR (5/14, 35% vs 3/46, 6.5% P0.005).
The duration of the operation was shorter in the primary
surgical group (17060 min) than in the neoadjuvant
group (22870 minutes, P0.033). The number of har-
vested lymph nodes was similar between the 2 groups
(median of 14.5 vs16.0, P0.800). Median hospital stay for
both groups was 4 days. Estimated blood loss of both the
primary surgical and neoadjuvant therapy groups was
similar (median 150 mL in primary surgical group vs. 200
mL in neoadjuvant therapy group, PNS). Neoadjuvant
therapy was not associated with an increase in perioper-
ative death, complications, or a need for reoperation (Ta-
ble 1).
Conversion resulted in a significantly extended length of
hospital stay compared with laparoscopically completed
procedures (median 5.5 vs 3.0 days, P0.009). The spe-
cific reasons for conversion were anatomic difficulty in 5
patients (3 in primary surgical vs 2 in the neoadjuvant
group), bulky tumor (1 in neoadjuvant), intraoperative
complications (3 in primary surgical), and an unspecified
reason from the operative record (1 in neoadjuvant). In-
traoperative complications included 2 instances of bleed-
ing not controllable by the laparoscopic technique and 1
ureteral injury. Conversion was associated with an in-
crease in operative morbidity, but not perioperative mor-
tality (Table 2).
Table 1.
Frequency of Perioperative Death, Complications, and
Conversion in Patients With (n  8) and Without (n  52)
Neoadjuvant Therapy*
Neoadjuvant Therapy

Perioperative death 1 (1.9%) 0 (0%)
Intraoperative complication 3 (5.7%) 0 (0%)
Postoperative complication 4 (7.7%) 0 (0%)
Reoperation 2 (3.8%) 0 (0%)
Conversion 7 (13.4%) 3 (37.5%)
*Data are expressed as frequency (percent). No statistically sig-
nificant differences detected.
Table 2.
Frequency of Perioperative Death and Complications in
Patients With Operative Conversion (n  10) and Those
Laparoscopically Completed (n  50)*
Conversion P OR

Perioperative death 0 (0%) 1 (10%) 0.167 -
Intraoperative complication† 0 (0%) 3 (30%) 0.004 -
Postoperative complication 3 (6%) 1 (10%) 0.528 1.7
Reoperation 1 (2%) 1 (10%) 0.308 1.6
*Data are expressed as frequency (percent).
†Statistical significance.
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Since it was first reported approximately 15 years ago,12
laparoscopic rectal resection has been performed increas-
ingly for benign and malignant rectal diseases.
Current practice depends on extrapolation of data from
colon cancer trials. So far, 5 randomized trials reported
survival data, all supporting the noninferiority of laparos-
copy.1,2,8,13,14 In fact, disease-free survival in the Spanish
trial2 was significantly higher in patients randomized to
the laparoscopic arm.
Such evidence is, however, not yet available to support
laparoscopic resection of rectal cancer. Retrospective
studies cautiously suggest the oncological adequacy of
laparoscopic rectal resections.6,7 An initial report on rectal
cancer data set in the British CLASSIC trial8 did not find
any significant drawbacks of laparoscopic rectal proce-
dures, but a trend towards a higher positivity of the cir-
cumferential resection margin was observed among those
receiving laparoscopic low anterior resection. Although
laparoscopic rectal resection appears safe, additional con-
cerns regarding increased conversion rates and associated
complications in laparoscopic rectal resection remain.8
Several other aspects of laparoscopic rectal surgery are
attractive for oncologic application. Total mesorectal ex-
cision is more commonly achieved in the laparoscopic
cohort,8 and appears to be technically easier, possibly due
to better visualization and magnification. Additionally, an
interesting phenomenon of decreased tumor growth after
laparoscopic surgery was observed in both animal stud-
ies15 and in vitro studies.13
The oncologic effectiveness of rectal cancer therapy is
further affected by adjuvant and neoadjuvant therapy.
Radiation therapy improves local control, whether given
pre-9,10 or postoperatively.16 Furthermore, in the Swedish
trial it improved both long-term overall survival and can-
cer-specific survival.10 No direct comparison of preoper-
ative versus postoperative radiotherapy for rectal cancer is
currently available. The German Rectal Cancer trial17 ac-
crued a satisfactory number of patients and should ad-
dress this issue.
Additionally, concurrent fluorouracil chemotherapy with
radiation is beneficial. Preoperative or postoperative flu-
orouracil-based chemotherapy improved local control but
has no effect on survival in a recent study of patients
receiving neoadjuvant radiotherapy.18 On the contrary,
adjuvant chemoradiation provides both superior local
control and improved survival, as compared with any
other combination treatment.19
Nevertheless, the addition of preoperative radiation ther-
apy led to increased perioperative mortality in some stud-
ies.10,11 Therefore, we conducted this study to analyze the
effects of neoadjuvant therapy on the feasibility and out-
comes in patients undergoing laparoscopic rectal resec-
tion for rectal cancer.
Our results indicate that patients undergoing operation
after neoadjuvant therapy are more frequently converted
to open procedures. Even so, this does not appear to be
associated with increased morbidity. Our overall conver-
sion rate of 16.7% compares favorably with the 25% to
34% rates reported in the other studies.7,8
We concur with the prior findings suggesting increased
complication prevalence among those patients who re-
quired conversion.8 Yet, the relationship of conversion
and complication rate is complex and only partially elu-
cidated.20 In addition, disturbing data from a Canadian
retrospective analysis21 pointed out significantly de-
creased survival in converted patients. In our study of 155
patients with colorectal cancer who underwent a laparo-
scopic procedure, no difference was found in oncologic
outcomes between laparoscopic completed and con-
verted procedures.22 More studies are required to investi-
gate the clinical and biological effects of conversion.
We acknowledge several shortcomings of the present
study. Selection of neoadjuvant therapy was nonrandom-
ized. If, in fact, patients with less favorable tumors were
preferentially selected for neoadjuvant therapy, this alone
can dramatically skew the results. The retrospective na-
ture and prolonged time span of the investigation can
certainly affect outcomes due to bias and changes in
clinical practice over the time period. We believe this
small observational study can serve as the basis for future
prospective randomized studies.
CONCLUSION
Expected results from the German rectal cancer trial and
planned ACOSOG trial hopefully will clarify the role of
laparoscopic surgery for rectal cancer. We believe that
laparoscopic rectal resection after neoadjuvant therapy for
rectal cancer has a higher conversion rate but no increase
in the risk of complications. Rectal cancer surgery is a
purely technical exercise and extensive experience is re-
quired before attempting these cases laparoscopically.
Further investigation of laparoscopic rectal surgery for
treatment of rectal cancer appears safe and is encouraged.
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